查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870943

化療誘發周邊神經神經病變治療市場：2025-2032年全球預測（按治療類型、給藥途徑、患者年齡層、治療持續時間和最終用戶分類）

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Therapy Duration, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，化療引起的周邊神經病變治療市場將成長至 18.8362 億美元，複合年成長率為 8.42%。

關鍵市場統計數據
基準年 2024 9.8584億美元
預計年份：2025年 10.6412億美元
預測年份 2032 18.8362億美元
複合年成長率 (%) 8.42%

權威摘要了影響腫瘤化療誘導周圍神經病變 (CIPN) 管理的不斷變化的臨床重點、護理路徑和相關人員壓力

化療引起的周邊神經病變（CIPN）是一個持續存在的臨床挑戰，它影響患者的生活品質，並使腫瘤治療路徑複雜化。隨著腫瘤治療方法的多樣化和生存期的延長，臨床醫生越來越重視在維持抗癌療效的同時緩解神經病變症狀的干涉措施。這種不斷變化的臨床需求促使人們更加關注多模式管理方法，即平衡藥物治療、非藥物介入和支持性護理策略。

重大變革正在重塑CIPN治療的臨床、創新軌跡和支付方預期。

近年來，多種因素共同作用，重塑了化療誘導周邊神經病變（CIPN）領域的格局，並正在改變治療方法的評估、應用和報銷方式。首先，對以患者為中心的終點指標和功能性結局的日益重視，使得非藥物療法與傳統藥物療法一樣，越來越被人們所接受。其次，神經生物學和生物標記發現的進步，使得預防和緩解症狀的方法更具針對性，臨床試驗能夠根據風險和作用機制對受試者進行分層。第三，支付者越來越要求提供可證實的真實世界療效數據，並整合治療路徑，這迫使研發人員設計出超越隨機對照試驗的證據包。

預測美國關稅對2025年的累積影響：供應鏈、進入和臨床營運分析

美國潛在的關稅變動可能會對化療誘導周邊神經病變 (CIPN) 治療生態系統產生連鎖反應，影響供應鏈成本、籌資策略和製造地地點。活性藥物原料藥、醫療設備或組件材料的進口關稅增加，可能會促使製造商和經銷商重新評估其採購來源、庫存策略和供應商多元化。因此，醫療機構和專科診所的採購計畫和單價可能會發生變化，進而影響藥物和醫療設備的採購決策。這凸顯了供應鏈韌性規劃的必要性，包括關鍵原料的地理多元化以及對上游生產風險的更高透明度。

基於細分市場的洞察揭示了治療方案、治療偏好、人口統計優先事項、治療持續時間考量以及醫療服務環境。

化療引起的周邊神經病變(CIPN) 的治療方案取決於治療方法的種類及其應用的臨床背景。根據治療類型，相關人員會權衡藥物治療（例如抗驚厥藥、抗憂鬱症和鴉片類藥物）與非藥物治療（例如針灸、物理治療和經皮神經電刺激 (TENS)）。這種權衡體現了療效、耐受性以及最大限度減少對癌症治療干擾的必要性。給藥途徑也會影響臨床決策。口服藥物常用於慢性症狀管理，而肌肉注射或靜脈注射等腸外給藥途徑則用於需要全身性控制的情況。局部用藥也是一種選擇，可提供局部緩解並具有良好的安全性。

區域觀點凸顯了與化療誘導周邊神經病變 (CIPN) 管理相關的醫療保健基礎設施、政策促進因素和創新採納模式的差異。

區域背景在化療誘導周邊神經病變 (CIPN) 管理中至關重要，因為不同地區的法規環境、報銷機制和醫療服務基礎設施差異顯著。在美洲，成熟的腫瘤網路、積極的臨床研究活動以及支付方以結果為導向的策略，都支持將基於指南的治療方案與醫療器材和數位健康解決方案相結合。而在其他地區，不斷變化的報銷模式和專科服務取得方面的差異正在影響治療方案的採納模式，因此需要能夠在各種醫療環境中實施的切實可行且經濟有效的干涉措施。

策略性企業級洞察，重點在於競爭定位、夥伴關係趨勢和創新重點領域，從而塑造 CIPN 解決方案

在CIPN領域營運的公司正透過多種途徑鞏固其市場地位，包括產品組合多元化、臨床合作以及技術賦能的服務模式。現有製藥公司傾向於拓展適應症、最佳化製劑配方，並支持進行療效比較研究，使其現有藥物在神經病變疼痛治療​​指南中脫穎而出。同時，專業的醫療設備開發商和數位醫療公司則優先考慮易用性、遠端監測以及證據生成，以證明其產品在真實臨床環境中的功能性益處。隨著越來越多的公司尋求降低成本、加快外用藥物和醫療設備耗材上市速度，契約製造和供應合作夥伴的重要性日益凸顯。

為臨床領導者、開發人員和商業負責人提供實用建議，以加速CIPN護理的推廣應用並改善患者預後。

優先考慮符合實際需求的證據，推廣納入患者報告結局、功能性指標和可操作終點的研究設計，這些指標能夠引起支付方和臨床醫生的重視。同時，投資於整合式醫療模式，將藥物治療和非藥物治療以及數位化症狀監測相結合，以支持門診和居家環境中的持續照護。為降低供應鏈和政策風險，制定關鍵投入品的多元化籌資策略，並與區域製造合作夥伴協作，以縮短前置作業時間並減少貿易中斷的影響。

對調查方法進行透明的摘要，該方法綜合、檢驗並整合證據，最終得出可操作的結論。

我們的研究途徑結合了對同儕審查的臨床文獻、監管指南和公共臨床試驗註冊庫的系統性回顧，以及與臨床專家、供應鏈專業人員和醫療政策相關人員的結構化訪談。我們的證據綜合優先考慮高品質的隨機對照試驗、Meta分析和指南建議，同時利用真實世界數據和觀察性研究來彌補不足，這些數據和研究突出了實施過程中遇到的挑戰。專家諮詢為我們提供了不同醫療機構的臨床實踐、實施障礙和未滿足需求的背景性解讀。

總之，該回顧強調了採取綜合方法來改善患者預後的緊迫性，同時克服商業性和政策方面的阻力。

化療引起的周邊神經病變(CIPN) 是一項涉及生物學、症狀管理和醫療保健系統設計的多方面挑戰。有效的因應措施需要整合策略，結合可靠的臨床證據、靈活的照護模式和穩健的供應鏈。隨著臨床重點轉向以病人為中心的療效和功能保護，相關人員必須協調研發、報銷和實施計劃，以在日常實踐中展現實際的影響。同樣重要的是，藥物研發者、醫療設備創新者、臨床醫生和支付方之間需要持續合作，將機制方面的進展轉化為可在各種醫療保健環境中應用的實用干預措施。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 加強標準治療和營養補充品在緩解化療誘導周邊神經病變 (CIPN) 症狀的應用
  • 擴大穿戴式神經刺激設備在化療引起的周邊神經病變（CIPN）家庭管理的應用
  • 生物標記的進步使得早期檢測和個人化治療方法成為可能，從而化療引起的周邊神經病變（CIPN）。
  • 增加對化療引起的周邊神經病變（CIPN）發炎介質的新型小分子抑制劑的投資
  • 間質幹細胞療法修復化療引起的神經病變的臨床進展
  • 製藥公司與數位療法公司合作，以提高化療誘導周邊神經病變（CIPN）患者的治療依從性
  • 採用人工智慧驅動的患者分層模型來改善化療引起的周邊神經病變（CIPN）的干涉效果

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章化療誘發周邊神經病變治療市場（依治療方式分類）

  • 非藥物治療
    • 針刺
    • 物理治療
    • 經皮電刺激（TENS）
  • 藥物治療
    • 抗驚厥藥
    • 抗憂鬱症
    • 鴉片類藥物

第9章 依給藥途徑分類的化療誘發周邊神經病變治療市場

  • 口服
  • 腸外
    • 肌肉內注射
    • 靜脈注射
  • 外用

第10章 依病患年齡層別分類的化療誘發周邊神經病變治療市場

  • 成人
  • 老年人
  • 兒童

第11章 依治療持續時間分類的化療誘發周邊神經病變治療市場

  • 長期治療
  • 短期治療

第12章化療誘發周邊神經病變治療市場（依最終用戶分類）

  • 居家醫療環境
  • 醫院
  • 專科診所

第13章化療誘發周邊神經病變治療市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章化療誘發周邊神經病變治療市場（依組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國化療誘發周邊神經神經病變治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • AlgoTherapeutix
    • Amgen Inc.
    • Array BioPharma Inc. by Pfizer Inc.
    • Artelo Biosciences, Inc.
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Bexion Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Eisai Inc.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Ltd.
    • Grunenthal GmbH
    • Heron Therapeutics, Inc.
    • Ipsen Pharma
    • Kyowa Kirin Co., Ltd.
    • Merck & Co., Inc.
    • Neuralace Medical
    • Novartis AG
    • Regenacy Pharmaceuticals LLC
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi SA
    • Serpin Pharma, LLC
    • Takeda Pharmaceutical Company Limited
    • Veloxis Pharmaceuticals, Inc.
Product Code: MRR-1A1A064C04DA

The Chemotherapy Induced Peripheral Neuropathy Treatment Market is projected to grow by USD 1,883.62 million at a CAGR of 8.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 985.84 million
Estimated Year [2025] USD 1,064.12 million
Forecast Year [2032] USD 1,883.62 million
CAGR (%) 8.42%

An authoritative synopsis of the evolving clinical priorities, care pathways, and stakeholder pressures shaping CIPN management across oncology settings

Chemotherapy-induced peripheral neuropathy (CIPN) remains a persistent clinical challenge that affects patient quality of life and can complicate oncology care pathways. As oncology regimens diversify and survivorship grows, clinicians increasingly prioritize interventions that reduce neuropathic symptoms while preserving anticancer efficacy. This evolving clinical imperative has elevated interest in multimodal management approaches that balance pharmacological therapy with non-pharmacological interventions and supportive care strategies.

Consequently, payers, health systems, and specialty clinics are aligning protocols to emphasize symptom relief, functional preservation, and continuity of cancer therapy. These stakeholders are also contending with constrained resources and competing priorities, which makes evidence-backed, cost-effective interventions especially attractive. In parallel, research communities are broadening the investigative lens to include preventive strategies, mechanistic biomarkers, and patient-reported outcome measures that better capture the lived experience of CIPN.

Taken together, the current landscape demands integrated thinking across clinical development, service delivery, and commercial strategy. By focusing on multidisciplinary solutions that are adaptable across care settings, stakeholders can better address unmet needs while managing complexity across regulatory, reimbursement, and supply chain dimensions.

Key transformative shifts reshaping clinical practice, innovation trajectories, and payer expectations in CIPN care

Over recent years the CIPN landscape has been reshaped by several converging shifts that alter how therapies are evaluated, adopted, and reimbursed. First, there is stronger emphasis on patient-centered endpoints and functional outcomes, which has expanded acceptance of non-pharmacological modalities alongside traditional drug therapies. Second, advances in neurobiology and biomarker discovery are informing more targeted approaches to prevention and symptomatic relief, enabling trials that stratify participants by risk and mechanism. Third, payer frameworks are increasingly demanding demonstrable real-world benefit and care pathway integration, prompting developers to design evidence packages that extend beyond randomized controlled trials.

Moreover, digital health tools and remote monitoring technologies have accelerated integration of home-based assessments, facilitating continuous symptom tracking and adaptive management. Meanwhile, growing scrutiny of opioid-based strategies has encouraged diversification toward anticonvulsants, antidepressant agents used for neuropathic pain, topical formulations, and device-based therapies. These combined forces are incentivizing cross-disciplinary partnerships among drug developers, device manufacturers, clinical networks, and health technology vendors, driving a more collaborative innovation model that emphasizes pragmatic, scalable solutions.

Analysis of the projected cumulative effects of prospective United States tariff measures on supply chains, access, and clinical operations in 2025

Potential tariff changes in the United States can reverberate through the CIPN therapy ecosystem by altering supply chain costs, procurement strategies, and manufacturing footprints. An increase in import duties on active pharmaceutical ingredients, medical devices, or component materials would likely prompt manufacturers and distributors to reassess sourcing, inventory strategies, and supplier diversification. In turn, providers and specialty clinics may experience changes in procurement timelines and unit costs that influence formulary decisions and device deployment plans. Consequently, there is a heightened need for supply chain resilience planning that includes geographic diversification of key inputs and greater visibility into upstream manufacturing risks.

At the clinical level, administrative burdens associated with altered customs processes and longer lead times could affect timely availability of topical agents, patches, and device consumables used in outpatient and home care settings. In addition, tariff-driven cost pressures may accelerate shifts toward generics, local manufacturing partnerships, or vertically integrated supply arrangements. From a strategic perspective, stakeholders should evaluate the interplay between trade policy, regulatory approvals, and domestic manufacturing incentives to preserve continuity of care and to mitigate unintended barriers to patient access.

Segmentation-driven insights that illuminate treatment choices, administration preferences, demographic priorities, duration considerations, and care delivery settings

Treatment selection for CIPN is shaped by a spectrum of therapeutic modalities and the clinical contexts in which they are deployed. Based on treatment type, stakeholders weigh pharmacological options such as anticonvulsants, antidepressants, and opioids against non-pharmacological alternatives that include acupuncture, physical therapy, and transcutaneous electrical nerve stimulation; this balancing act reflects efficacy evidence, tolerability, and the need to minimize interference with cancer therapy. Route of administration considerations also influence clinical decision-making, with oral agents frequently used for chronic symptom management, parenteral options employed when systemic control is required including intramuscular and intravenous approaches, and topical formulations offering localized relief with favorable safety profiles.

Patient age group is a critical filter for therapy design and delivery, as adults, geriatric patients, and pediatric populations present distinct risk-benefit profiles, comorbidity burdens, and adherence challenges. Therapy duration further influences care plans, where short-term interventions target acute or transient neuropathic episodes and long-term therapy prioritizes sustained symptomatic control and functional preservation. End-user environments shape implementation feasibility and resource allocation; home care settings favor user-friendly, low-burden interventions that support self-management, hospitals must integrate CIPN protocols into complex oncology workflows, and specialty clinics often deliver multimodal, multidisciplinary care with access to device-based therapies and procedural options.

Understanding these intersecting segmentation dimensions enables more precise pathway design, targeted evidence generation, and tailored commercialization strategies that resonate with clinicians, caregivers, and patients across diverse clinical contexts.

Regional perspectives that highlight differing healthcare infrastructures, policy drivers, and innovation adoption patterns relevant to CIPN management

Geographic context matters deeply for CIPN management, as regions demonstrate distinct regulatory environments, reimbursement mechanisms, and care delivery infrastructures. In the Americas, established oncology networks, robust clinical research activity, and payer emphasis on outcomes have supported integration of guideline-based therapies alongside device and digital health solutions. Elsewhere, evolving reimbursement models and varied access to specialty services shape adoption patterns and demand pragmatic, cost-conscious interventions that can be delivered across diverse care settings.

Within Europe, Middle East & Africa, regulatory harmonization in some markets contrasts with fragmented procurement and variable specialist availability in others, making regionally tailored evidence and pricing strategies essential. In the Asia-Pacific region, rapid capacity expansion in oncology services, growing clinical trial activity, and increasing investment in domestic manufacturing create both opportunities and operational complexities for companies seeking regional scale. Across all regions, differences in clinician training, patient expectations, and health system priorities require adaptive commercialization and partnership approaches to ensure therapies reach appropriate patient populations while aligning with local standards of care.

Strategic company-level insights highlighting competitive positioning, partnership trends, and innovation focus areas shaping CIPN solutions

Companies active in the CIPN domain are pursuing multiple pathways to strengthen their market positions, including portfolio diversification, clinical collaboration, and technology-enabled service models. Established pharmaceutical manufacturers often focus on expanding label indications, optimizing delivery formulations, or supporting comparative effectiveness research to differentiate familiar agents within neuropathic pain guidelines. Specialized device developers and digital health firms emphasize usability, remote monitoring, and evidence generation that demonstrates functional benefits in real-world settings. Contract manufacturers and supply partners are increasingly important as firms seek cost-efficient production and faster time-to-provider for topical formulations and device consumables.

Across the ecosystem, strategic alliances and clinical partnerships are common as stakeholders combine therapeutic expertise with procedural skills and digital capabilities. Intellectual property strategies lean toward formulation patents, device innovations, and data-driven approaches to outcome measurement. Meanwhile, competitive pressures from generics and off-label prescribing drive a focus on value demonstration, patient stratification, and niche positioning that highlights safety, tolerability, and integration into multidisciplinary care pathways.

Actionable recommendations for clinical leaders, developers, and commercial strategists to accelerate adoption and improve patient outcomes in CIPN care

Prioritize evidence that aligns with real-world clinical needs by designing studies that incorporate patient-reported outcomes, functional measures, and pragmatic endpoints that payers and clinicians find compelling. Simultaneously, invest in integrated care models that combine pharmacological therapies with non-pharmacological modalities and digital symptom monitoring to support continuity of care in outpatient and home environments. To mitigate supply chain and policy risk, develop diversified sourcing strategies for critical inputs and engage with regional manufacturing partners to reduce lead times and exposure to trade disruptions.

Engage proactively with payer bodies and clinical guideline committees to ensure that dossiers reflect the full spectrum of clinical value, including safety, quality-of-life impact, and health system efficiencies. Forge interdisciplinary partnerships across oncology, neurology, rehabilitation, and palliative care to accelerate adoption of multimodal protocols and to foster clinician champions. Finally, tailor commercialization strategies to the nuances of regional markets and care settings, emphasizing scalable training programs, implementation support, and outcomes tracking that demonstrate sustained patient benefit.

Transparent research methodology summary describing how evidence was integrated, validated, and synthesized to support actionable insights

The research approach combined systematic review of peer-reviewed clinical literature, regulatory guidance, and publicly available clinical trial registries with structured interviews of clinical experts, supply chain specialists, and health policy stakeholders. Evidence synthesis prioritized high-quality randomized controlled trials, meta-analyses, and guideline recommendations while supplementing gaps with real-world evidence and observational studies that illuminate implementation challenges. Expert consultations provided contextual interpretation of clinical practice realities, adoption barriers, and unmet needs across different care settings.

Data validation included cross-referencing therapeutic mechanisms, administration routes, and standard-of-care practices against clinical guidelines and specialist input to ensure consistency. Where policy or trade scenarios were analyzed, publicly available regulatory notices and trade documentation were reviewed to ground implications in verifiable developments. Finally, insights were iteratively reviewed by multidisciplinary advisors to refine recommendations and to ensure the final narrative supports pragmatic decision-making for clinicians, developers, and commercial teams.

Concluding synthesis that underscores the urgency of integrated approaches to improving patient outcomes while navigating commercial and policy headwinds

CIPN presents a multifaceted challenge that spans biology, symptom management, and health system design. Effective responses require integrated strategies that combine robust clinical evidence, adaptable care models, and resilient supply chains. As clinical priorities shift toward patient-centered outcomes and functional preservation, stakeholders must align development, reimbursement, and implementation plans to demonstrate meaningful benefit in routine practice. Equally important is the sustained collaboration among drug developers, device innovators, clinicians, and payers to translate mechanistic advances into pragmatic interventions that are accessible across care settings.

In summary, the path forward is characterized by opportunity for stakeholders who can generate relevant evidence, design for real-world implementation, and build operational resilience in the face of policy and supply uncertainties. By embracing multidisciplinary approaches and regionally tailored strategies, organizations can make measurable improvements in symptom control, patient quality of life, and continuity of cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing integration of nutraceutical combinations with standard care for CIPN symptom relief
  • 5.2. Expansion of wearable neurostimulation devices for at-home management of chemotherapy induced peripheral neuropathy
  • 5.3. Advancements in biomarkers enabling early detection and personalized CIPN treatment regimens
  • 5.4. Growing investment in novel small molecule inhibitors targeting inflammatory mediators of CIPN
  • 5.5. Clinical progression of mesenchymal stem cell therapies aimed at repairing chemotherapy induced nerve damage
  • 5.6. Collaboration between pharmaceutical and digital therapeutics companies to enhance CIPN patient adherence
  • 5.7. Adoption of AI driven patient stratification models to improve CIPN intervention outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Type

  • 8.1. Non-Pharmacological Treatments
    • 8.1.1. Acupuncture
    • 8.1.2. Physical Therapy
    • 8.1.3. Transcutaneous Electrical Nerve Stimulation
  • 8.2. Pharmacological Treatments
    • 8.2.1. Anticonvulsants
    • 8.2.2. Antidepressants
    • 8.2.3. Opioids

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Route of Administration

  • 9.1. Oral
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
  • 9.3. Topical

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Therapy Duration

  • 11.1. Long-Term Therapy
  • 11.2. Short-Term Therapy

12. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by End-User

  • 12.1. Home Care Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. AlgoTherapeutix
    • 16.3.3. Amgen Inc.
    • 16.3.4. Array BioPharma Inc. by Pfizer Inc.
    • 16.3.5. Artelo Biosciences, Inc.
    • 16.3.6. Asahi Kasei Corporation
    • 16.3.7. Astellas Pharma Inc.
    • 16.3.8. Bexion Pharmaceuticals, Inc.
    • 16.3.9. Bristol-Myers Squibb Company
    • 16.3.10. Eisai Inc.
    • 16.3.11. F. Hoffmann-La Roche Ltd
    • 16.3.12. GlaxoSmithKline PLC
    • 16.3.13. Glenmark Pharmaceuticals Ltd.
    • 16.3.14. Grunenthal GmbH
    • 16.3.15. Heron Therapeutics, Inc.
    • 16.3.16. Ipsen Pharma
    • 16.3.17. Kyowa Kirin Co., Ltd.
    • 16.3.18. Merck & Co., Inc.
    • 16.3.19. Neuralace Medical
    • 16.3.20. Novartis AG
    • 16.3.21. Regenacy Pharmaceuticals LLC
    • 16.3.22. Regeneron Pharmaceuticals, Inc.
    • 16.3.23. Sanofi S.A.
    • 16.3.24. Serpin Pharma, LLC
    • 16.3.25. Takeda Pharmaceutical Company Limited
    • 16.3.26. Veloxis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CHEMOTHERAPY INDUCED PER